<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157819</url>
  </required_header>
  <id_info>
    <org_study_id>OP-002-000</org_study_id>
    <nct_id>NCT01157819</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis</brief_title>
  <acronym>Once-a-day</acronym>
  <official_title>Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro (0.3% Ciprofloxacin Otic Foam) Compared to Twice-Daily Dosing of Ciloxan (0.3% Ciprofloxacin Otic Solution) in Patients With Acute External Otitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otic Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otic Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro (0.3%&#xD;
      Ciprofloxacin Otic Foam), used once-daily for 7 days for the treatment of Acute Diffuse&#xD;
      Otitis Externa, compared to commercial ear drops used twice daily for 7 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute otitis externa (AOE) is defined as a diffuse inflammation of the external ear canal,&#xD;
      which may also involve the pinna and/or the tympanic membrane. AOE is one of the most common&#xD;
      infections encountered by otolaryngologists, pediatricians and family physicians. Diagnosis&#xD;
      of AOE requires rapid onset (generally within 48 hours) of symptoms and signs of ear canal&#xD;
      inflammation which includes: A) otalgia (often severe), itching or fullness, sometimes&#xD;
      accompanied by reduced hearing or jaw pain; B) tenderness of the tragus and/or pinna; and C)&#xD;
      diffuse ear canal edema with or without erythema, sometimes accompanied by ear discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure confirmed by significant reduction or absence of the disease symptoms a) Otalgia, b) tenderness with movement of pinna, and c) edema/ear canal occlusion</measure>
    <time_frame>within 7 days after completion of treatment that lasts 7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Otitis Externa</condition>
  <condition>Otorhinolaryngologic Diseases</condition>
  <condition>Ear Diseases</condition>
  <condition>Otitis</condition>
  <arm_group>
    <arm_group_label>Ciloxan Ear Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Foam Otic Cipro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this study arm will receive the experimental product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Ciprofloxacin Ear Drops</intervention_name>
    <description>4 gtt b.i.d. for 7 days.</description>
    <arm_group_label>Ciloxan Ear Drops</arm_group_label>
    <other_name>Ciloxan</other_name>
    <other_name>Ciprofloxacin</other_name>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FoamOtic Cipro</intervention_name>
    <description>0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days</description>
    <arm_group_label>Foam Otic Cipro</arm_group_label>
    <other_name>Ciprofloxacin</other_name>
    <other_name>Cipro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 and older eligible to sign by themselves.&#xD;
&#xD;
          -  Have a clinical diagnosis of Acute Otitis Externa based on clinical observation and of&#xD;
             presumed bacterial origin.&#xD;
&#xD;
          -  Intact tympanic membrane&#xD;
&#xD;
          -  Unilateral Acute Otitis Externa&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or sensitivity to Ciprofloxacin or other quinolones.&#xD;
&#xD;
          -  Clinical Diagnosis of chronic suppurative otitis media (CSOM), acute otitis media&#xD;
             (AOM), involvement of middle ear effusion (MEE).&#xD;
&#xD;
          -  Patient has the non intact tympanic membrane.&#xD;
&#xD;
          -  Patient has a serious underlying disease.&#xD;
&#xD;
          -  Patients with known history of immune dysfunction/deficiency and those receiving&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
          -  Patients with history of Diabetes mellitus.&#xD;
&#xD;
          -  Bilateral Acute Otitis Externa.&#xD;
&#xD;
          -  Patients with more than 80% of the ear canal occluded.&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  Overt fungal Acute Otitis Externa.&#xD;
&#xD;
          -  Local ear canal abnormalities such as abscess, granulation or polyps.&#xD;
&#xD;
          -  Congenital abnormalities of the external auditory canal or obstructive bony exostosis&#xD;
             in the treated ear.&#xD;
&#xD;
          -  Mastoid or other suppurative non-infectious ear disorder (e.g. cholesteatoma) in the&#xD;
             treated ear.&#xD;
&#xD;
          -  Seborrheic dermatitis or other dermatological conditions of the external auditory&#xD;
             canal which would complicate evaluation.&#xD;
&#xD;
          -  Current Infection requiring systemic antimicrobial therapy.&#xD;
&#xD;
          -  Current or previous use of topical or oral antibiotics (within 3 days) or long-acting&#xD;
             antibiotics (within 7 days).&#xD;
&#xD;
          -  Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days of entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehudah Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edith Wolfson Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bet Roter Clinic, Clalit Health Services</name>
      <address>
        <city>Holon</city>
        <zip>58320</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>July 4, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>March 14, 2011</last_update_submitted>
  <last_update_submitted_qc>March 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Rodrigo Yelin (Study Director)</name_title>
    <organization>Otic Pharma LTD</organization>
  </responsible_party>
  <keyword>swimmer's ear</keyword>
  <keyword>ear drops</keyword>
  <keyword>ear foam</keyword>
  <keyword>otic foam</keyword>
  <keyword>ear infection</keyword>
  <keyword>ear pain</keyword>
  <keyword>ear inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Ear Diseases</mesh_term>
    <mesh_term>Otitis Externa</mesh_term>
    <mesh_term>Otorhinolaryngologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

